Kornimate/medical-research-clean huggingface dataset:
dermal substitution in pediatric burns

Conditions: Burns; Burn Scar

Summary: the standard treatment of deep dermal to full thickness burns is surgical removal of the burn followed by skin transplantation. dermal substitutes are increasingly used in the treatment of deep burns to replace lost dermis. preservation of the collagen and elastin in the acellular human dermal substitute glyaderm provides a more elastic scar. it is unknown what the effect of glyaderm on scar quality is in a solely paediatric population. the objective of this case series is to investigate scar maturation and scar quality when applying glyaderm in deep dermal to full thickness burns in a pediatric population aged ≤15 years old.


Eligibility criteria:
inclusion criteria: 1. age ≤15 years old 2. burn wounds requiring skin grafting 3. written informed consent provided by 1. the participant's parent(s)/guardian (\<12 years of age) 2. the participant's parent(s)/guardian and the participant itself (12-15 years old) exclusion criteria: 1. burn wound of ≤30 cm2 2. infected burn wounds: clinical symptoms in combination with positive wound swabs 3. patients/parents with insufficient knowledge of the dutch or english language, since they would not be able to complete the posas questionnaire.

Keywords: burns scar quality pediatric
comparison of the effects of an hypertonic solution with ringer lactate on right ventricular function following cardiac surgery

Conditions: Right Ventricular Impaired Function; Hypovolemia

Summary: this study is a phase iii, randomized, controled, parallel groups, single blinded, clinical trial that aims at comparing the improvement of right ventricular function after administration of a hypertonic solution versus ringer lactate following cardiac surgery. adults patients admitted to grenoble university hospital for elective cardiac surgery under cardiopulmonary bypass, in sinus rhythm and with swan ganz monitoring will be included. patients needing fluid expansion in the first three hours after surgery will be randomized in two groups : one receiving ringer lactate (10 ml/kg), the other receiving hypertonic saline solution (3 ml/kg). right ventricular function measured with swan ganz catheter, 30 minutes after fluid expansion will be the primary outcome.


Eligibility criteria:
inclusion criteria: * elective valvular or coronary surgery * under cardiopulmonary bypass * patient requiring swan ganz catheter monitoring * patient in sinus rhythm * patient requiring post-operative volemic expansion * echographic criteria of hypovolemia, without hypervolemia exclusion criteria: * pulmonary hypertension (spap \> 60mmhg) * no pre-operative sinus rhythm * emergency surgery * age \< 18 years * chronic renal failure treated with dialysis * severe hypernatremia

Keywords: cardiopulmonary bypass swan ganz fluid expansion hypertonic saline solution
zno nanoparticles coated orthodontic molar tube

Conditions: Evaluations, Diagnostic Self; Antimicrobial; Orthodontic Appliance Complication; Bacterial Overgrowth; Dental White Spot; Plaque Induced Gingivitis; Plaque, Dental

Summary: orthodontic treatment is an elective procedure to improve the patient's dentofacial appearance. the complex design of fixed appliances provides a platform that leads to increased plaque accumulation around orthodontic brackets. so, the risk to develop demineralization area adjacent to orthodontic brackets is a major barrier in achieving this goal. oral hygiene is greatly complicated following the placement of fixed orthodontic appliances. molar tube in place are considered for nearly all patients experiencing fixed orthodontic therapy over the whole treatment period, which normally lasts 1.5 to 2 years. to the best of the authors' knowledge, the application and antimicrobial efficacy of zinc oxide (zno) nanoparticles coating on orthodontic molar tube material has not been integrated clinically. white spot lesions during orthodontic treatment have a documented etiology. briefly, the accumulation of plaque and food around brackets, bands, wires, and other attachments caused decreased ph and increased s. mutans colonization, which led to the possibility of clinical demineralization. the aims of study are to assess the antimicrobial effect of nanoparticle coated stainless steel orthodontic molar tube material (omt) with zinc oxide (zno) nanoparticles in relative to uncoated orthodontic molar tube (uomt) against the streptococcus. mutans\& lactobacllius bacteria that cause white spot lesion around the fixed orthodontic appliance. .

aim: the aim of this prospective randomized clinical trial is to assess the antimicrobial efficacy of nanoparticle coating stainless steel orthodontic molar tube (omt) with zinc oxide (zno) nanoparticles in relative to uncoated orthodontic molar tube (uomt). objectives: 1. compare the antimicrobial properties of the zno nanoparticle coated omt in relative to uncoated orthodontic molar tube (uomt). 2. evaluate and compare the clinical bond failure rate between the coated omt and the uomt. the null hypothesis is that there is no significant difference in the antimicrobial effects and the rate of bond failure between the non-coated and coated stainless steel orthodontic molar tube using zno nps.

Eligibility criteria:
inclusion criteria: * patients who are seeking or under orthodontic treatment with fixed appliances subjects must be healthy \&well fit medically. * subjects with no signs or symptoms of oral mucosal disease. * subjects should not receive oral antimicrobials or antibiotic therapy for more than 3 months prior to sample enrolling. * non-pregnant or lactating female patient. * subjects is not smokers exclusion criteria: * patients with a greater tendency to accumulate plaque (e.g., having congenital anomalies such as cleft lip and palate) or undergo orthognathic surgery

Keywords: nanoparticles zinc oxide nanoparticle coating orthodontic molar tube electrophoretic deposition cell epd cell nanomaterials antimicrobial effect bacterial culture
effects of otago-based multicomponent exercise on sarcopenia in pre-frailty older adults in nursing homes: a randomized controlled trial

Conditions: Pre-Frailty; Sarcopenia in Elderly

Summary: the objective of this clinical trial is to understand the efficacy of a targeted exercise program (otago exercise program+strength training) in elderly people with prefrailty and sarcopenia. the trial aims to answer the following main questions: * is oep+st effective in elderly people with prefrailty and sarcopenia? * in what areas did participants improve during the oep+st intervention? researchers will randomly assign participants to an experimental group (oep+st) and a control group (daily care only) for comparison to see the effects of this intervention. participants in the eg group will: * exercise 3 times a week for 1 hour each time (including 10 minutes of warm-up, 40 minutes of exercise and 10 minutes of stretching) at the same time, it is necessary to walk for 30-40 minutes three times a week. it lasts for three months. * test and record their condition (including frailty, body composition, physical function, quality of life) before and after the experiment.


Eligibility criteria:
inclusion criteria: * participants were diagnosed with pre-existing frailty (fried score 1-2); at the same time, they were also diagnosed with sarcopenia (according to awgs asian sarcopenia diagnostic criteria 2019 edition: grip strength: male \< 28kg, female \< 18kg; smi: male \< 7.0kg/m2, female \< 5.4kg/m2; walking speed ≤1.0 m/s; 5 sit-up test times ≥12s); simple mental status examination (mmse score ≥21); there are no absolute contraindications to physical exercise (chest pain, chest tightness, palpitations, dyspnea, syncope, high fever, severe cough, severe diarrhea, gross hematuria, radiating pain in waist and legs, fracture, etc.). exclusion criteria: * uncontrolled high blood pressure. coronary artery disease. rheumatoid arthritis. type 2 diabetes. respiratory diseases and lung diseases. are taking or have used antibiotics and/or antifungal therapy in the past 4 weeks. unwillingness to stick to a prescribed schedule.

Keywords: pre-frailty sarcopenia multicomponent exercise elderly people
validation of a score of predictive factors for complete resection in platinum-sensitive recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: the purpose of this study is to validate a score developed by the ago-ovar for complete resection of the tumor

the multicentre retrospective study ago-desktop ovar 1 investigated in a multicentre-setting the question of prognostic factors for a successful (i.e. complete) debulking for recurrence. that way, a hypothesis for a score with 3 factors could be developed: * ps ecog = 0 * tumor-free after primary surgery (if unknown: figo i/ii) * ascites \< 500 ml. the goal of this study is to evaluate in a prospective multicentre setting, to what extent this retrospectively defined ago-score has predictive validity. the criterion aimed at is therefore the rate of complete tumor resections if the three score characteristics are present in invasive epithelial platinum-sensitive ovarian-, fallopian tube- or primary peritoneal cancer. this study will be the second in a series of three: (1) hypothesis building for a potential predictive score for resectability, (2) prospective confirmation of the ago-score, and (3) application of the ago-score as inclusion criteria for eligible patients in whom a formal comparison of the role of secondary debulking of relapsed ovarian cancer could be performed.

Eligibility criteria:
inclusion criteria: * patients with recurrence of invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer of any initial stage who have relapsed after a tumor-free interval of at least 6 months after completion of first-line therapy. the same interval applies to patients with second relapse who are enrolled after completed platinum-containing re-induction therapy. * women aged \> 18 years * patients who have given their signed and written informed consent to data transmission and -processing exclusion criteria: * patients with non-epithelial tumors as well as borderline tumors * patients who undergo second-look surgery or completion surgery after end of chemotherapy or during the interval * only for the study collective: patients with second malignancies who have been treated by laparotomy, as well as other neoplasias, if the treatment could interfere with the treatment of relapsed ovarian cancer * patients with a third recurrence * patients with so-called platinum-refractory tumor, i.e. progression during chemotherapy or recurrence within 6 months after end of former platinum-containing therapy

Keywords: ovarian cancer recurrence surgery
cognitive rehabilitation of blast traumatic brain injury (tbi)

Conditions: Traumatic Brain Injury; Cognitive Symptoms

Summary: the purpose of this study is to investigate the efficacy of a structured rehabilitation program on cognitive function and quality of life in individuals with blast-induced traumatic brain injury (btbi).

the most common impairments following blast-induced traumatic brain injury (btbi) are cognitive deficits in the domain of executive functioning, learning and memory, and functional and psychosocial disabilities that are closely related to these cognitive deficits. there are no treatment protocols available to address the multiple cognitive impairments in btbi, but cognitive rehabilitation has proven efficacious in the treatment of non-blast tbi. the cognitive training modules the investigators plan to evaluate have improved organization and memory function in patients with non-blast tbi, but it is unknown whether their efficacy exceeds that of programs that focus only on education and support. this study is a between group comparison of a cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function, and an active control group receiving educational intervention geared at personal management of tbi-related symptoms.

Eligibility criteria:
inclusion criteria: * operation enduring freedom (oef)/operation iraqi freedom (oif) active-duty personnel or veterans exposed to blast * meets criteria for mild tbi * loss of consciousness (loc) of 30 min or less * age: 21- 50 exclusion criteria: * evidence of penetrating head injury * history of previous neurological diagnosis * history of previous psychotic disorder prior to the blast exposure * hearing or vision impairment

Keywords: rehabilitation outcome cognitive treatment tbi
efficacy and safety of 2 dosing regimens of t1225 eye drops 1.5% versus oral azithromycin in treatment of trachoma

Conditions: Trachoma

Summary: to assess in children the efficacy and safety of 2 dosing regimens of t1225 1.5% eye drops, in comparison to a reference product, single-dose oral azithromycin (azm) 20 mg/kg, for the treatment of active trachoma. evaluation of clinical efficacy was primary (% of clinical cure at day 60 in per protocol set), microbiological evaluation was secondary

the aim of the present study was to compare the efficacy of the dosing regimen which was demonstrated in pharmacokinetic studies to be the best candidate for trachoma treatment (t1225 1.5% eye drops bid for 3 days) with a shorter duration of treatment (t1225 1.5% eye drops bid for 2 days) and with a single oral administration of azm (20 mg/kg) in patients suffering from active trachoma. the study was to be performed in approximately 600 children (aged 1 to 10 years) from guinea conakry and pakistan.

Eligibility criteria:
inclusion criteria: * male or female aged 1-10 years; * written informed consent by legally acceptable representative; * tf+ ti0 (trachomatous inflammation - follicular) or tf+ti+ (trachomatous inflammation - follicular and intense) on simplified world health organisation (who) grading system exclusion criteria: * trichiasis or corneal opacity; * palpebral deformation; * clinically significant ocular abnormality; * ocular infection; * organic amblyopia; * hypersensitivity to treatments' components; * immunosuppressive conditions; * systemic azm or steroids; * topical ophthalmic antibiotics within 3 months; * other systemic antibiotics within 1 month; * topical (ocular, nasal, bronchial etc.) treatments within 1 week; * systemic non-steroidal anti-inflammatory drugs on day before day 0
posterior circulation astral prognostic score

Conditions: Stroke Ischemic; Stroke Acute; Posterior Circulation Brain Infarction; Risk Score

Summary: the goal of this study is to develop a prognostic score for ischemic posterior circulation strokes, based on our previous work on with the astral scores (acute stroke registry and analysis of lausanne) on overall stroke prognosis, intracranial occlusion, recanalization and stroke recurrences. the main question it aims to answer is the modified rankin score in 3 months after the event. participants will be patients with acute ischemic stroke of the posterior circulation with mrs priot to event \<3. all the data will be collected retrospectively from patients included in the astral registry between january 2003 and december 2021. the astral registry will be used as the derivation cohort of the score. demographics, acute glucose, nihss score and acute imaging of each participant will be used from the derivation cohort in order to create an integer-based prognostic score. after internal validation, we plan to validate the score in external stroke registries to show its validity.


Eligibility criteria:
inclusion criteria: * isolated posterior circulation strokes based on clinical or/and imaging evidence. * arriving within 24h at hospital since last proof of good health. exclusion criteria: * no available data for 3 months modified rankin score * modified rankin score≥3 prior the event
self-guided personalized treatment for women

Conditions: Disordered Eating

Summary: the investigators plan to collect preliminary data on the feasibility, acceptability, and user uptake of a personalized self-guided mobile intervention for disordered eating (de) and test the initial clinical efficacy of this intervention. women (n=50) who endorse significant de will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones. the investigators will assess engagement with the modules throughout two months and administer baseline, week 5, and week 8 assessments for acceptability, uptake, and initial clinical efficacy (e.g., de symptoms, anxiety, quality of life). the investigators will also complete a focus group (n=10) with a subset of users to receive input on the mobile-application assessment and ease of self-guided intervention modules.


Eligibility criteria:
inclusion criteria: * endorse disordered eating (score of 2.3 or above on ede-q6) * age 18-65 * ability to read and write english * own a smartphone or tablet exclusion criteria: * active mania * active suicidality * active psychosis

Keywords: treatment therapy anorexia nervosa bulimia nervosa binge eating disorder atypical anorexia nervosa other specified feeding and eating disorder
evaluation of the phased radio frequency ablation system

Conditions: Persistent Atrial Fibrillation

Summary: victory af is an ide, prospective global, multi-center, single arm, controlled, unblinded, investigational clinical study. the purpose of this clinical study is to evaluate the risk of procedure and/or device related strokes in subjects with persistent or long-standing persistent atrial fibrillation (af) undergoing ablation with the phased rf system.


Eligibility criteria:
inclusion criteria: * history of symptomatic persistent or long-standing persistent atrial fibrillation * failure of at least one anti-arrhythmic drug exclusion criteria: * structural heart disease * prior ablation in left atrium for af * known sensitivities (or allergy) to heparin, warfarin, contrast media * contraindicated for mri * invasive cardiovascular procedure performed or planned within 3 month period of ablation procedure

Keywords: ablation atrial fibrillation radio frequency
post concussion symptoms risk stratification tool

Conditions: Post-Concussion Syndrome

Summary: patients with persisting concussion symptoms (pcs) have a multitude of different symptoms. some patients are at risk of prolonged symptoms but currently there is no tool to assist in identifying patients at high risk. intensive, multidisciplinary intervention is time-consuming and expensive and may not be warranted for all pcs patients, so it is essential to identify early on which patients are at risk of prolonged symptoms. the aim of this study is to improve the quality of care delivered to patients, especially those who are at high-risk of prolonged pcs by early identification and treatment of all the symptoms. the purpose of this research is to validate the use of a persisting concussion symptoms (pcs) risk stratification tool (rst).

the information from 500 hundred concussion patients were used to develop the pcs rst. this is a screening tool that will assist in predicting patient outcomes by allocating patients with pcs into a low, medium and high risk group for prolonged pcs symptoms. this categorization would help target those patients at high risk of prolonged symptoms with a multidisciplinary individualized treatment and evaluate the effectiveness of it on return to work and recovery. for this research study, we ask workers who have had concussions and are categorized as high high risk (with pcs rst) for prolonged pcs symptoms to undergo individualized treatments and we will examine their recovery and return to work. the study will involve 75 patients with persisting concussion symptoms from the canadian concussion centre clinics and altum health concussion clinic at toronto western hospital.

Eligibility criteria:
inclusion criteria: 1. age between 18-60 years old 2. clinical diagnosis of pcs for 1-12 months with at least 3 symptoms 3. must be employed at time of injury 4. full-time or part-time worker prior to concussion and cannot return to work 5. must speak english and be sufficiently literate to complete questionnaires and perform assessments 6. must be able to give consent exclusion criteria: 1. abnormalities on mri such as contusion, hemorrhages, siderosis, or other non-traumatic conditions 2. history of neurological conditions (e.g. stroke, seizures) or major psychiatric disease
the safety, efficacy and tolerability of remote ischemic preconditioning as a therapy to dmd

Conditions: Duchenne Muscular Dystrophy (DMD)

Summary: background: duchenne muscular dystrophy (dmd) is an x chromosome recessive hereditary disease and mainly characterized by progressive muscle weakness and atrophy. glucocorticoid is the only proven effective medicine,while side effects limit its use. recent studies have shown that the vascular density in the dmd patients' muscle is decreased,so muscle are in ischemic and anoxic. remote ischemic preconditioning(ripc) can improve the capable of resistanting ischemia and hypoxia and maybe a potential therapy for dmd patients. methods: 100 patients (aged 2 to 6 years)will be divided into two groups(treatment and control groups) randomly. treatment group will receive an ripc stimulus (inflation of a blood pressure cuff on the bilateral thighs to 150 mm hg for four 5-minute intervals) while control group will receive a similar stimulus (inflation of a blood pressure cuff on the bilateral thighs to 40 mm hg for four 5-minute intervals). serum kinase level ,blood levels of myoglobin, evaluation of motor function(four steps test;6-minute walking test) and mri of lower limbs）at 0 days, 3 days, 3months ,6months. purpose： 1. to evaluate the safety and tolerability of remote ischemic preconditioning for dmd patients 2. to identify the effectiveness of remote ischemic preconditioning for dmd patients.


Eligibility criteria:
inclusion criteria:genetic analysis of dmd; from 2 to 6 years old ;without other diseases . - exclusion criteria: other congenital diseases;upper respiratory infection, gastroenteritis, vaccination, trauma. -

Keywords: ischemic preconditioning sefety efficacy dmd
hypersensitivity reactions during anesthesia

Conditions: Allergy

Summary: researchers are trying to study the natural history of allergic reactions during anesthesia and its causes and risk factors.


Eligibility criteria:
inclusion criteria: * patients over age 18 undergoing surgery at mayo clinic florida exclusion criteria: * minors under age 18 * unable to consent